Somewhat Positive News Coverage Somewhat Unlikely to Impact Editas Medicine (EDIT) Share Price
News articles about Editas Medicine (NASDAQ:EDIT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Editas Medicine earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.4474247193716 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Editas Medicine, Inc. (EDIT) : Are you searching Analysts Rated Stock – Wall Street Morning (wallstreetmorning.com)
- Editas Medicine to Participate in Upcoming Investor Conferences – GlobeNewswire (press release) (globenewswire.com)
- Editas Medicine, Inc. (EDIT) Cynical EPS Growth Performer For This Year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Outline of Different Gauges: Editas Medicine, Inc. (EDIT), FuelCell Energy, Inc. (FCEL) – Market Movers (financialqz.com)
Several equities research analysts have issued reports on EDIT shares. Zacks Investment Research raised Editas Medicine from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Friday, November 10th. ValuEngine downgraded Editas Medicine from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub downgraded Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $30.73.
Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm had revenue of $6.28 million for the quarter, compared to analyst estimates of $2.66 million. During the same period in the prior year, the business posted ($0.59) EPS. The firm’s quarterly revenue was up 553.0% compared to the same quarter last year. sell-side analysts expect that Editas Medicine will post -2.92 EPS for the current year.
In other news, CEO Katrine Bosley sold 8,333 shares of Editas Medicine stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $36.18, for a total transaction of $301,487.94. Following the completion of the sale, the chief executive officer now owns 1,338,898 shares of the company’s stock, valued at $48,441,329.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew A. F. Hack sold 14,649 shares of Editas Medicine stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $24.68, for a total value of $361,537.32. Following the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $123,400. The disclosure for this sale can be found here. Insiders have sold 84,648 shares of company stock valued at $2,687,509 in the last three months. Insiders own 19.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Editas Medicine (EDIT) Share Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/09/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-editas-medicine-edit-share-price.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.